908 Devices is a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis.
908 Devices makes products ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices.
908 Devices was co-founded in 2012 by Kevin J. Knopp, Christopher D. Brown, Steve Araiza, Andrew Bartfay, Michael Jobin, and Scott Miller. The company is headquartered in Boston, MA.
908 Devices is democratizing chemical analysis by way of mass spectrometry, offering point-of-need chemical analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices.
908 Devices' devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets.
908 Devices is backed by Saudi Aramco Energy Ventures, Northpond Ventures, Razor's Edge Ventures, Schlumberger, ARCH Venture Partners and others. The company has raised a total of $66.8M in funding to date. 908 Devices went public on Dec 18, 2020, with a $524M IPO valuation the company raised $130M from the listing.